Therapy Advisor®

June 4, 2019

Glytec Developing Novel Solution for Selection and Dosing of All Diabetes Medications

New product will be the market’s first and only to enable optimization of ALL diabetes medications, insulin and non-insulin alike.

In spite of greater than 80 medications currently available in the U.S. to treat diabetes, less than half of the estimated 22 million people prescribed one or more are maintaining blood sugar levels within the acceptable range. The consequences not only impact health status and quality of life, they add to the growing economic burden of diabetes estimated in 2017 at $327 billion. With multiple patent allowances for its novel Therapy Advisor® software-as-a-medical-device and active engagement in the FDA 510(k) process, Glytec is poised to improve these clinical and financial outcomes by helping providers more easily and efficaciously select and dose all varieties of diabetes medications. No solution of like kind is currently available, Therapy Advisor® will be the first.

April 9, 2019

Glytec Receives Another Patent Allowance for Therapy Advisor®

The company is expanding its software-as-a-medical-device platform to support the optimization of ALL diabetes medications.

The United States Patent and Trademark Office has granted Glytec another patent allowance for systems and methods related to a product registered under the brand name, Therapy Advisor®. Currently under development, the new product will extend the company’s core competencies beyond insulin optimization to include oral, inhaled and non-insulin injectable diabetes medications.

January 9, 2018

USPTO Grants Glytec Patent Allowance for Computer-Guided Selection and Dosing of All Diabetes Medications

The new patent allowance addresses personalized optimization of insulin and non-insulin medications alike.

Long recognized as the market leader in enterprise software solutions for insulin management, Glytec is expanding its intellectual property protections with a new patent allowance that addresses the optimization of all diabetes medications, including oral and non-insulin injectable varieties. The patent allowance, issued by the United States Patent and Trademark Office, comprises an intricate series of 24 claims that describe personalized computer-guided selection and dosing of any prescribed diabetes therapy regimen, whether insulin only, non-insulin only or combination.